Premium
State‐of‐the‐art preclinical testing of the OMEGA TM left atrial appendage occluder
Author(s) -
De Backer Ole,
Hafiz Hussein,
Fabre Aurelie,
Lertsapcharoen Pornthep,
Srimahachota Suphot,
Foley David,
Sondergaard Lars
Publication year - 2021
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.29331
Subject(s) - medicine , in vivo , left atrial appendage occlusion , biomedical engineering , atrial fibrillation , embolization , appendage , ostium , 3d printed , occlusion , surgery , nuclear medicine , anatomy , microbiology and biotechnology , warfarin , biology
Abstract Objectives This study aimed to present a new approach of thorough preclinical testing of a novel left atrial appendage (LAA) occluder device. Background The development of a safe and effective LAA occluder has been shown to be challenging. Methods The novel OMEGATM LAA occluder (Eclipse Medical, Ireland) was tested in a porcine model and three‐dimensional (3D) human LAA models – this as a prelude to its first‐in‐human use. Results In a first series of in‐vivo experiments, the OMEGATM LAA occluder was shown to have a satisfactory device biocompatibility in a porcine model. The design of the OMEGATM device was further refined and optimized following three more series of in‐vivo experiments. The second generation OMEGATM device was designed with thinner wires, leading to a profile reduction. Based on in‐vitro testing of different OMEGATM device sizes implanted at different depths in human three‐dimensional (3D) LAA models, it could be determined that (1) the landing zone should be measured at a median depth of 12 mm from the LAA ostium; (2) the distal self‐retaining inverted cup should have 10%‐25% compression to minimize device embolization risk; and (3) the disc should be slightly inverted, i.e. pulled into the LAA, to promote complete LAA occlusion. The combined in‐vivo and in‐vitro testing resulted in an optimized pre‐procedural planning of the first‐in‐human case treated with the OMEGATM device. Conclusions This series of carefully planned in‐vivo and in‐vitro experiments allowed demonstration of the safety and efficacy of the OMEGATM LAA occluder. This approach of thorough preclinical testing of medical devices may reduce the risk of complications in first‐in‐human cases and may become the standard approach for device development and preclinical testing in the future.